Successful long-term replacement therapy with FXIII concentrate (Fibrogammin® P) for severe congenital factor XIII deficiency: A prospective multicentre study

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 6, 2011, Pages 1264-1266

  Dreyfus, M ^a   Barrois, D ^b   Borg, J Y ^c   Claeyssens, S ^d   Torchet, M F ^e   Arnuti, B ^f   Pautard, B ^g  

^a BICÊTRE HOSPITAL   (France)

^b CAP Santé 49   (France)

^c HÔPITAL CHARLES NICOLLE   (France)

^d CHU PURPAN   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f CENTRE HOSPITALIER DE VALENCE   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13 CONCENTRATE; FIBROGAMMIN P; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; BIOLOGICAL ACTIVITY; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BRAIN HEMORRHAGE; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; LETTER; LONG TERM CARE; MALE; MULTICENTER STUDY; NEWBORN; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SCHOOL CHILD; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT RESPONSE;

EID: 79958060213     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04281.x     Document Type: Letter

References (13)

1. Ivaskevicius V, Seitz R, Kohler HP, Schroeder V, Muszbek L, Ariens RA, Seifried E, Oldenburg J. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97: 914-21.
2. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. Semin Thromb Hemost 2009; 35: 426-38.
3. Chandra S, Groener A, Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb Res 2002; 105: 391-400.
4. Eshghi P, Mahjour SB, Naderi M, Dehbozorgian J, Karimi M. Long-term prophylaxis in patients with factor XIII deficiency complicated by intracranial haemorrhage in Iran. Haemophilia 2010; 16: 383-5.
5. Lovejoy AE, Reynolds TC, Visich JE, Butine MD, Young G, Belvedere MA, Blain RC, Pederson SM, Ishak LM, Nugent DJ. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108: 57-62.
6. Reynolds TC, Butine MD, Visich JE, Gunewardena KA, MacMahon M, Pederson S, Bishop PD, Morton KM. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers. J Thromb Haemost 2005; 3: 922-8.
7. Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14: 1190-200.
8. Lusher J, Pipe SW, Alexander S, Nugent D. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010; 16: 316-21.
9. Nugent DJ. Prophylaxis in rare coagulation disorders - factor XIII deficiency. Thromb Res 2006; 118 (Suppl. 1): S23-8.
10. Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U. ETRO working party on factor XIII deficiency in Europe: status and perspectives. Study Group. Semin Thromb Hemost 1996; 22: 415-8.
11. Brackmann HH, Egbring R, Ferster A, Fondu P, Girardel JM, Kreuz W, Masure R, Miloszewski K, Stibbe J, Zimmermann R, Krzensk U, Hoos A. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995; 74: 622-5.
12. Abbondanzo SL, Gootenberg JE, Lofts RS, McPherson RA. Intracranial hemorrhage in congenital deficiency of factor XIII. Am J Pediatr Hematol Oncol 1988; 10: 65-8.
13. Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, Collins PW, Kitchen S, Dolan G, Mumford AD. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.